Incannex Flat on Looking Ahead to Clinical Trial

Incannex Healthcare Inc. (NASDAQ: IXHL) shares barely budged Wednesday. The New York-based company, a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announced that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA), on schedule as of June 16.

This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July, reinforcing confidence in the program’s momentum and execution.

CEO Joel Latham, commented, "Achieving database lock on schedule demonstrates our strong clinical capabilities and commitment to advancing a much-needed therapy for obstructive sleep apnoea.

IHL-42X represents a breakthrough opportunity to address a condition affecting hundreds of millions of people globally, with no approved oral pharmacological treatment available. We are excited by what lies ahead."

This morning’s news release also said the RePOSA Phase 2 trial is evaluating IHL-42X in patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). The proprietary fixed-dose combination therapy is designed to reduce apnoea episodes, improve sleep quality, and offer a patient-friendly alternative to current treatment options.

IXHL shares inched up 0.6 cents, or 2.8%. to 23 cents.